Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

Figure 2

Overall survival and progression free survival of the A24(+) and A24(−) groups. All enrolled patients had received the vaccination without knowing HLA-A status, and the HLA-A genotypes were used for the key-open at analysis point. The OS (A) and PFS (B) were evaluated for each of the HLA-A*2402-positive (24(+)) and -negative (24(−)) groups for the sub-group analysis. MST, median survival time.

Back to article page